(1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
(1995). Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party.
(1994). Clearance of circulating endothelin-1 by ETB receptors in rats.
(2008). Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
(2008). Endothelin receptor antagonists in pulmonary arterial hypertension.
(2009). Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism.
(2009). Endothelin-1 impairs alveolar epithelial function via endothelial ETB receptor.
(2008). Endothelin: 20 years from discovery to therapy.
(2010). Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwichcultured human hepatocytes.
(2002). Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
(2008). Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
(2000). Molecular cloning and characterization of the murine bile salt export pump.
(2002). Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
(1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137
(2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
(2007). Results of European post-marketing surveillance of bosentan in pulmonary hypertension.
(2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231
(2008). The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
(2007). Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
(1999). Transaminase elevation on placebo during Phase I trials: prevalence and significance.